TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Response rate better than very good partial response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical Improvement of Target Lesions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of patients with clinical characteristics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: post prandial metabolism of chylomicrons
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Proportion of participants with resolved incontinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers of Antibodies Against Each Dengue Virus Serotype
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fatigue Severity
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Prosthesis donning and doffing
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: enzyme activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Assessment of degree of caesarean wound healing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Assessment of Caesarean wound keloid formation & degree of scarring (MVSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Assessment of Caesarean wound keloid formation & degree of scarring (Colour photograph)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Change in postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of patient with negative conversion in nasopharyngeal swab
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Proportion of subjects achieving complete wound closure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Patient disability
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: plasma concentration of fentanyl and propofol
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase II dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TC/HDL ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Change in Recognition Ratings
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change in Overall Anxiety Severity and Impairment Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Median days alive and out of the hospital
Endpoint domain: Mortality/survival
Primary endpoint: Occurrence of dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: Sperm retrieval rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Number of patients with microvascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of patients with cardiovascular complications
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Safety of OMP-18R5
Endpoint domain: Adverse events/effects
Primary endpoint: Systolic Pressure Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Diastolic Pressure Value
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Subjects With Human Serum Bactericidal Activity (hSBA) Titers ≥1:4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: number of patients with functional graft
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: number of patients alive
Endpoint domain: Mortality/survival
Primary endpoint: Postpartum haemorrhage (less than or equal to 500 ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Postpartum haemorrhage (less than or equal to 1000 ml)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Use of additional uterotonic therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Maximally tolerated dose (MTD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended phase 2 dose (RP2D)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants experiencing serious adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants discontinuing study drug due to adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Responders (Dichotomised: responder/non-responder)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Major complication occurency
Endpoint domain: Adverse events/effects
Primary endpoint: Percent of Patients Experiencing an Unacceptable Toxicity
Endpoint domain: Adverse events/effects
Primary endpoint: Quality of life score, part Physical Health component
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Quality of life score, part Mental Health component
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in handgrip strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area under the Curve from time 0 to infinity [AUC(0-∞)]
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-D (Hamilton Rating Scale for Depression)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: IDS-SR (Inventory of Depressive Symptomatology - Self-Report)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Safety and toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Maintenance of Complete Healing of eGERD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: objective response rate (ORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recurrence of symptoms of APACG
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for IOP lowering medication
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Worst Postbaseline Tolerability (Erythema)
Endpoint domain: Adverse events/effects
Primary endpoint: Worst Postbaseline Tolerability (Scaling)
Endpoint domain: Adverse events/effects
Primary endpoint: Worst Postbaseline Tolerability (Dryness)
Endpoint domain: Adverse events/effects
Primary endpoint: Worst Postbaseline Tolerability (Stinging/Burning)
Endpoint domain: Adverse events/effects
Primary endpoint: serum inflammatory biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Signal interpretability
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Device ease-of-use
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Number of Opioid Pills Consumed
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Proportion of volunteers with treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Surgical or Other Invasive Procedures Defined as Good or Excellent Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Preoperative predictive factors
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Complaints About Pain, Vomiting, Dyspepsia, and/or Dysphagia
Endpoint domain: Adverse events/effects
Primary endpoint: Amount of leg blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Fugl-Meyer assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Delayed memory performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Duration of antipsychotic treatment during follow up
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: TMS-EEG change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hamilton Depression Rating Scale (HamD)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Gait cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Who Seroconvert to Each of the HPV Types Contained in the Vaccine
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants With an Injection-site Adverse Event (AE)
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Non-Injection Site (Systemic) AE
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of Participants With a Vaccine-related AE
Endpoint domain: Adverse events/effects
Primary endpoint: Patient exposure time following an incontinence event
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Treatment satisfaction with insulin pump therapy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: changes in the oral stereognosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy measured by radiological exams
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percent of Time of a Somato-sensory Cortex Coactivation Pattern
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in Brain Connectivity With Acupuncture Treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Patient Temperature at the Time of Incision
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of accurate polyp histology predictions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of accurate diagnosis of sessile serrated polyps/adenoma
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CD8 count (cells/mm^3) in the tumor microenvironment
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Objective reactive rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of participants that result in sufficient pharmacodynamic criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean Log10 Change in HIV RNA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in Health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Release of pro-and anti-inflammatory cytokines
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage of Participants Passing DBPCFC
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self empowerment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in blood concentration of total and specific IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change in quality of life measured by Lebelscore
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in quality of life measured by SNOT-22
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Proportion of Patients Achieving a Validated Investigator Global Assessment Scale Score of 0 or 1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of Patients Achieving EASI-75
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fugl-Meyer Assessment Upper Extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Functional Reserve of Liver
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in rebound hyperglycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Adverse cardiovascular events
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Post-operative follow-up period
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change from baseline in pain (visual analogue scale)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from baseline in Foot-Function-Index-Revised (FFI-R)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With InterStim Implantation
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Freedom of target lesion failure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative State-Trait Anxiety Inventory Response
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of allergic diseases
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Difference in GDM prevalence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Difference in macrosomia rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Glucose tolerance status 3 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Patients With Crossmatch Conversion (Positive to Negative)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Projection of line C on the costiform processes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Image Quality of MRA Images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety/tolerability as measured by number of patients with adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Maximum tolerated dose as measured by frequency of dose limiting toxicities
Endpoint domain: Adverse events/effects
Primary endpoint: Difference from baseline in the number of free mutant DNA in blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Change From Baseline in Mean Diurnal IOP
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Subjective Refraction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reading Performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Number of Participants with Chronic Disease Events
Endpoint domain: Adverse events/effects
Primary endpoint: Plasma Vz
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seropositive rate of EV71 neutralizing antibody-1
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Mean change in BCdVA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Infant cognitive development
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Detection of abnormal vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in AS-OCTA results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Pain pressure threshold (PPT)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cerebral Blood Flow Autoregulation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Presence of antibodies against SARS-COV2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: AUC(INF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Average number of injections omitted
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Knowledge on AI
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Experience with AI
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Opinion on AI
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change From Baseline to Month 3 in Objectively Assessed Physical Activity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change From Baseline to Month 3 in Peak Joint Load Symmetry During Walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mental state grade
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Recurrence Free Survival (RFS)
Endpoint domain: Mortality/survival
Primary endpoint: Recurrence Free Survival (RFS) Rate
Endpoint domain: Mortality/survival
Primary endpoint: MRI Related Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Lead Related Complication Rate
Endpoint domain: Adverse events/effects
Primary endpoint: Change in Body composition
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Behavioural assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Treatment Burden Questionnaire (TBQ)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Older Patient Assessment of Care for Chronic Conditions (O-PACIC)
Endpoint domain: Life impact
Endpoint subdomain: Delivery of care
Primary endpoint: CollaboRATE
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Health Care Utilization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Percent Agreement of Interpretation
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Maximum tolerated dose (MTD) of NZ-DTX Depot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Recommended Phase 2 dose (RP2D) of NZ-DTX Depot
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Cluster of Differentiation 4 (CD4+) T cell subpopulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: fasting glycemia
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: 1 Year Relapse Free Survival
Endpoint domain: Mortality/survival
Primary endpoint: Major clinical events due to graft vascular illness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Treatment Engagement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Change in Intense-Exuberant Stomach Fire Syndrome scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Gingival recession depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Primary Graft Dysfunction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in AISRS total score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cognitive Function as Assessed by the National Adult Reading Test (NART)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Cognitive Function as Assessed by the Hopkins Verbal Learning Test (HVLT), Total Recall Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Daytime Sleepiness as Assessed by Epworth Sleepiness Scale (ESS)
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Intra-ocular pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Need for Hospitalization
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in blood oxygenation level dependency (BOLD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Accuracy of normal- and low-dose CTPA
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Colorectal Cancer Screening Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: NYHA functional classification status
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: hemodynamic performance of the valve
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Chalder's Fatigue Scale Score
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Change in Right Ventricular:Left Ventricular ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Sustained Virological Response (SVR12)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Seated Computerized Dynamic Posturography (sCDP)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraocular Pressure Variation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Maximum tolerated dose (MTD) or recommended Phase II dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Preliminary safety and tolerability profile
Endpoint domain: Adverse events/effects
Primary endpoint: humoral antibody responses
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: accuracy of haemoglobin measurement methods
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Obtaining tumor tissue and blood specimens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Obstructive Apnea Hypopnea Index
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes